

Emyria Launches New Clinic - The Empax Centre - Dedicated to Advanced Mental Health Treatment and Research

HIGHLIGHTS

Emyria has opened a new, state-of-the-art facility - **The Empax Centre** - and expanded its clinical service capacity dedicated to the delivery and development of new treatments for mental health such as MDMA-assisted therapy (MDMA-AT) for PTSD.

Led by some of Australia's first authorised MDMA-AT prescribers ^{1, 2}, the Empax Centre features advanced technology for superior patient care and data-driven research.

Emyria's first Empax Centre is aiming at achieving operational profitability by H2 2024 with potential for national and global scalability via further site expansion.

Empax Centre to initially target critical gaps in care for resistant PTSD, with a strategy to expand therapeutic offerings using the same foundational infrastructure.

Emyria Limited (ASX: EMD) ("Emyria", or the "Company") focused on delivering and developing new treatments for mental health and select neurological conditions, is proud to announce the opening of the Empax Centre, a state-of-the-art facility dedicated to the delivery and development of new treatments for mental health such as psychedelic-assisted therapies. This purpose-built centre combines patient-centred design and cutting-edge technology and increases Emyria's clinical service capacity to support the treatment and research of complex mental health conditions such as Post-Traumatic Stress Disorder (PTSD).

Named to reflect empathy and homage to its founding entities, Emyria and The Pax Centre, the Empax Centre is dedicated to the delivery and Real-World evaluation of new mental health treatments such as MDMA-assisted therapy for individuals with difficult-to-treat PTSD. The Empax Centre reflects the Company's commitment to addressing unmet needs in mental health and, at full capacity, is expected to substantially increase the Company's care delivery and research revenues as well as directly support the Company's innovation pipeline of new care models and proprietary drug therapies.


Market Potential - Unmet Needs in PTSD Treatment:

The Empax Centre's founding mission is to serve a significant yet underserved population — those grappling with resistant forms of PTSD, including many first responders. With an estimated 1 million Australians living with PTSD ³, and a substantial portion not responding to standard treatments, the Empax Centre is uniquely positioned to address this gap by supporting new treatment research such as the recently announced study with charity Reach Wellness, to evaluate MDMA-AT for first responders with PTSD ⁴. The Empax Centre will be the trial location for the Reach Wellness study.


Select features




Multiple, dedicated therapy rooms



Discrete AV and data capture



Full sound-proofing for privacy



In-room & headphone audio; AI-generated music

emyria

Innovation and Excellence in Care

Led by pioneers in the field, including two of Australia's first authorised prescribers of MDMA-assisted therapy, the Empax Centre has a supporting team of over 14 clinicians specially trained in psychedelic-assisted therapy. The facility is therefore designed to support the unique requirements of these treatments including dedicated spaces to ensure patient comfort and safety over extended sessions, complemented by advanced audio-visual (AV) monitoring and an AI-generated music system for an unparalleled therapeutic experience.

Commitment to Research and Evidence-Based Innovation

The Centre is expected to become a centre of excellence for care delivery and research and development and a core focus of the Empax Centre is to capture robust clinical evidence while providing unparalleled patient care. This data-driven approach supports Emyria's long-term innovation agenda which involves actively developing new and improved care models as well as novel drug treatments inspired by MDMA⁵.

Commercialisation Strategy

The Empax Centre is expected to support a range of new therapies and research in addition to MDMA-AT, such as psilocybin-assisted therapy for treatment-resistant depression. Furthermore, the Centre has been designed as a blueprint for scalable mental health treatment nationwide and globally. Consequently, the Empax Centre is expected to support multiple revenue streams from both direct patient care and sponsored clinical research with the first Centre anticipated to reach operating break-even by the second half of 2024. Additional centres are in early stages of planning.

There are currently no products containing psilocybin or MDMA included in the Australian Register of Therapeutic Goods (ARTG) that have been evaluated by the TGA for safety, quality and efficacy. However, there is now sufficient evidence that psilocybin and MDMA will potentially be effective in the treatment of treatment-resistant depression (TRD) and PTSD, respectively, for certain patients. In particular, clinical trials have shown promise when they are used in combination with psychotherapy in strictly controlled medical settings.

Long-term Innovation Pipeline

As part of Emyria's unique strategy, the Company utilises revenues and data generated from its suite of clinical services to support proprietary innovation efforts comprising new care models and novel drug development. The Company is currently advancing an ambitious MDMA analogue development program with global partners, the University of Western Australia (UWA) and the National Institute of Health (NIH) in the USA.⁵ The Company has also been given a clear search report from the international patent examiner⁷, indicating the novelty and potential patentability of a massive library of novel MDMA analogues with the potential to become a new treatments for PTSD.

Dr. Michael Winlo, CEO: *"The Empax Centre demonstrates Emyria's commitment to lead the way in mental health innovation within the regulatory frameworks set by the TGA.*

Our extensive research and development efforts, particularly in MDMA-assisted therapy for PTSD, have shaped our strategic approach towards scalability and profitability - essential for the widespread adoption and success of these innovative treatments.

This new facility not only signifies our commitment to improving mental health care but also highlights our firm belief in the transformative potential of our treatments."

emyria

Risks associated with the use of Psilocybin, MDMA and Ketamine ⁶

All medicines carry risks and specialist prescribers, such as registered psychiatrists, are best placed to assess the suitability of a new medication against a patient's individual circumstances and medical history before proceeding. Adverse effects of psilocybin can include temporary increase in blood pressure and a raised heart rate. Adverse effects of MDMA include high blood pressure, increased pulse rate, faintness, and panic attacks, and in some rare cases it can cause loss of consciousness or trigger seizures. Other side effects include involuntary jaw clenching, decreased appetite, restless legs, nausea, headache, sweating and muscle/joint stiffness. These effects of psilocybin and MDMA are unlikely at low doses in the treatment regimens used in psychedelic-assisted psychotherapy while appropriately managed in a controlled environment with direct medical supervision.

Ketamine has potential to cause acute physical, psychiatric, psychotomimetic and cognitive side effects following a single dose and cumulative side effects resulting from repeated dosing. The majority of studies of ketamine in depression have examined side effects only acutely and after a single dose, with limited studies examining safety in repeated doses. Acute physical adverse effects of ketamine include hypertension, sedation, nausea or vomiting, headache, poor coordination, poor concentration, dizziness, blurred vision, and restlessness. The potential of ketamine to induce acute hypertension, lower urinary tract dysfunction and interstitial cystitis, and alter hepatic function, and noting that ketamine is metabolised by the liver, warrant screening for relevant pre-existing conditions.

References:

1. See ASX release 10 January 2024
2. See ASX release 05 April 2024
3. <https://www.phoenixaustralia.org/news/ptsd-awareness-day-2022/>
4. See ASX release 03 April 2024
5. See ASX release 28 February 2024
6. <https://www.ranzcp.org/getmedia/75baa529-2b71-419f-993a-2ff64ede50fe/cm-use-of-ketamine-in-psychiatric-practice.pdf>

This release has been approved by the Board of Emyria.

For further information, investment opportunities, or more about our approach to mental health treatment, please contact:

Managing Director
Michael Winlo
+61 (0) 8 6559 2800
mwinlo@emyria.com

Media Contact
Haley Chartres
+61 (0) 423 139 163
haley@hck.digital

Corporate Advisor
Sufian Ahmed
+61 (0) 412 316 162
info@62capital.com.au

Emyria Limited is focused on developing and delivering new treatments for mental health and select neurological conditions through an integrated model of direct clinical services and drug development:

generates

Emyria Healthcare: Evidence-based treatment for patients not finding relief from conventional care while also helping evaluate emerging new therapies like MDMA-assisted therapy for PTSD ¹


informs

Emyria Data: Robust and ethically-sourced Real-World Data gathered with patients and used to improve Emyria's unique therapy and drug development programs.

Emyria's Pipeline: One of the world's largest libraries of unique MDMA-like compounds developed in partnership with the University of Western Australia seeking new psychedelic-assisted therapies and treatments for neurological diseases as well as highly potent dose forms of Ultra-Pure CBD seeking registration for a range of mental health and neuroscience indications.

EMYRIA'S INTERACTIVE INVESTOR HUB

[Investorhub.emyria.com](https://investorhub.emyria.com) Interact with Emyria's announcements and updates by asking questions and comments, which our team can respond to where possible.



CAUTIONARY NOTE ON FORWARD-LOOKING STATEMENTS Any statements in this press release about future expectations, plans and prospects for the Company, the Company's strategy, future operations, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company's ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company's ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represents the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.